LPL Financial LLC Makes New Investment in Janux Therapeutics, Inc. (NASDAQ:JANX)

LPL Financial LLC purchased a new position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 8,202 shares of the company's stock, valued at approximately $439,000.

Other large investors have also recently added to or reduced their stakes in the company. KLP Kapitalforvaltning AS acquired a new stake in shares of Janux Therapeutics in the 4th quarter valued at approximately $450,000. Sei Investments Co. purchased a new position in shares of Janux Therapeutics in the 4th quarter valued at about $502,000. Virtu Financial LLC grew its position in Janux Therapeutics by 17.5% during the fourth quarter. Virtu Financial LLC now owns 8,769 shares of the company's stock worth $469,000 after buying an additional 1,306 shares during the period. Magnetar Financial LLC purchased a new position in Janux Therapeutics in the fourth quarter valued at about $723,000. Finally, Teacher Retirement System of Texas boosted its stake in shares of Janux Therapeutics by 127.2% during the 4th quarter. Teacher Retirement System of Texas now owns 11,815 shares of the company's stock worth $633,000 after acquiring an additional 6,614 shares in the last quarter. 75.39% of the stock is owned by hedge funds and other institutional investors.

Janux Therapeutics Stock Down 1.9 %

Shares of NASDAQ JANX traded down $0.63 on Thursday, hitting $32.58. The company had a trading volume of 72,274 shares, compared to its average volume of 845,783. Janux Therapeutics, Inc. has a 12-month low of $22.52 and a 12-month high of $71.71. The firm has a market capitalization of $1.93 billion, a P/E ratio of -27.82 and a beta of 3.27. The business has a 50 day moving average of $29.83 and a two-hundred day moving average of $42.82.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. On average, sell-side analysts anticipate that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Insider Buying and Selling at Janux Therapeutics

In other Janux Therapeutics news, Director Ra Capital Management, L.P. bought 110,206 shares of the stock in a transaction on Friday, March 7th. The stock was purchased at an average price of $31.02 per share, for a total transaction of $3,418,590.12. Following the completion of the purchase, the director now directly owns 10,141,287 shares in the company, valued at approximately $314,582,722.74. This trade represents a 1.10 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Andrew Hollman Meyer sold 3,334 shares of the firm's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $32.15, for a total transaction of $107,188.10. Following the completion of the transaction, the insider now owns 82,139 shares in the company, valued at approximately $2,640,768.85. The trade was a 3.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 10,002 shares of company stock worth $348,203 in the last ninety days. 29.40% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

JANX has been the topic of several research reports. William Blair reissued an "outperform" rating on shares of Janux Therapeutics in a report on Friday, January 10th. HC Wainwright restated a "buy" rating and issued a $70.00 target price on shares of Janux Therapeutics in a report on Monday, March 3rd. Wedbush reiterated an "outperform" rating and set a $76.00 price target (up from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. Finally, Scotiabank lowered their price target on Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating for the company in a report on Friday, February 28th. One analyst has rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $95.25.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.